Preclinical

Nav1.8 SLiP

Nav1.8 ankyrin-binding-domain short lipidated peptide

Neurology, Pain & Sensory Biology

A Nav1.8-targeted lipidated peptide reduced neuronal hyperexcitability and pain-like behavior in mice. Here is what the preclinical evidence does—and does not—show.

Research status: Preclinical research only — no human clinical trials published

Deep Dives on Nav1.8 SLiP

Start here for the plain-English articles connected to this peptide.

Evidence Interpretation10 min read

Can a Lipidated Peptide Quiet Neuropathic Pain? What the Nav1.8–Ankyrin-3 Mouse Study Shows

A Nav1.8-targeted lipidated peptide reduced neuronal hyperexcitability and pain-like behavior in mice. Here is what the preclinical evidence does—and does not—show.

Read article

Quick Facts

Origin: Experimental Nav1.8-derived lipidated research peptide described by Powell et al. in Cell Reports Medicine (2026)
Category: Neurology, Pain & Sensory Biology

Mechanisms

Discussed in relation to peptide for neuropathic pain mouse study research
Evidence quality varies by claim and should be separated from consumer marketing
Clinical relevance, safety, and long-term effects may remain uncertain

Research Areas